Sugi Predict

Sugi Predict / Compounds / Cep-1347

Cep-1347

Cep-1347

SCHEMBL12047710

CCSCc1ccc2c(c1)c1c3c(c4c5cc(CSCC)ccc5n5c4c1n2[C@H]1C[C@](O)(C(=O)OC)[C@]5(C)O1)CNC3=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MAP3K10MAP3K11MAP3K12MAP3K13MAP3K9

The experimentally established mechanism targets of Cep-1347. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K11 known ✓ Q16584 14/20 1.00
▸ MAP3K9 known ✓ P80192 12/20 1.00
▸ MAP3K10 known ✓ Q02779 8/20 1.00
▸ KDR P35968 4/20 1.00
▸ FLT1 P17948 1/20 1.00
▸ FLT4 P35916 1/20 1.00
▸ DLK1 P80370 1/20 1.00
▸ NTRK1 P04629 8/20 0.93
▸ PRKD3 O94806 3/20 0.74
▸ PRKCG P05129 3/20 0.74
▸ PRKCB P05771 3/20 0.74
▸ PRKCA P17252 3/20 0.74
▸ PRKCH P24723 3/20 0.74
▸ PRKCI P41743 3/20 0.74
▸ PRKCE Q02156 3/20 0.74
▸ PRKCQ Q04759 3/20 0.74
▸ PRKCZ Q05513 3/20 0.74
▸ PRKCD Q05655 3/20 0.74
▸ PRKD1 Q15139 3/20 0.74
▸ MYLK Q15746 3/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cep-1347 SCHEMBL29381680 1.00 MAP3K11 (1.00) MAP3K11MAP3K9MAP3K10KDRFLT1
Cep-1347 SCHEMBL8263437 1.00 MAP3K11 (1.00) MAP3K11MAP3K9MAP3K10KDRFLT1
Cep-1347 SCHEMBL30198505 1.00 MAP3K11 (1.00) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL13140134 0.97 MAP3K11 (0.93) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL13142263 0.97 MAP3K11 (0.93) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL12445000 0.95 MAP3K11 (0.90) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL5964631 0.93 MAP3K11 (0.86) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL29366906 0.91 MAP3K11 (1.00) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL15289975 0.91 MAP3K11 (1.00) MAP3K11MAP3K9MAP3K10KDRFLT1
SCHEMBL13234118 0.90 MAP3K11 (0.81) MAP3K11MAP3K9MAP3K10KDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180760-B2 Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders THE JOHNS HOPKINS UNIVERSITY (US) 2021-11-23 — — US disclosed
US-20150030572-A1 IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2015-01-29 — — US disclosed
US-8771682-B2 Methods and compositions for reducing interleukin-4 or interleukin-13 signaling Technische Universtität Dresden (DE) 2014-07-08 — — US disclosed
US-8729065-B2 Crystalline forms of a pharmaceutical compound CEPHALON, INC. (US) 2014-05-20 — — US disclosed
WO-2013134766-A2 IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2013-09-12 — — WO disclosed
US-20130084275-A1 Methods and Compositions for Reducing Interleukin-4 or Interleukin-13 Signaling TECHNISCHE UNIVERSITAT DRESDEN (DE) 2013-04-04 — — US disclosed
US-8076320-B2 Crystalline forms of a pharmaceutical compound CEPHALON, INC. (US) 2011-12-13 — — US disclosed
US-8076320-B2 Crystalline forms of a pharmaceutical compound CEPHALON, INC. (US) 2011-12-13 — — US disclosed
US-20110124629-A1 Crystalline Forms of a Pharmaceutical Compound CEPHALON, INC. (US) 2011-05-26 — — US disclosed
US-20090239271-A1 FERMENTATION BROTH EXTRACTION OF K-252A ABBOTT LABORATORIES (US) 2009-09-24 — — US disclosed
US-20090239271-A1 FERMENTATION BROTH EXTRACTION OF K-252A ABBOTT LABORATORIES (US) 2009-09-24 — — US disclosed
WO-2008122038-A1 REGULATING AUTOPHAGY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2008-10-09 — — WO disclosed
US-20070191339-A1 Crystalline forms of a pharmaceutical compound H. LUNDBECK A/S (DK) 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180760-B2 Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders ALDH1A2, NLN, CLN6 MAP3K11 461/4885MAP3K9 467/4885MAP3K10 262/4885
US-20130084275-A1 Methods and Compositions for Reducing Interleukin-4 or Interleukin-13 Signaling IL4, IL2RA, STAT6 MAP3K11 185/4885MAP3K9 293/4885MAP3K10 232/4885
US-20070191339-A1 Crystalline forms of a pharmaceutical compound KLK1, CYP2C9, KLK13 MAP3K11 1750/4885MAP3K9 1490/4885MAP3K10 1627/4885
US-20110124629-A1 Crystalline Forms of a Pharmaceutical Compound KLK1, CYP2C9, KLK13 MAP3K11 1750/4885MAP3K9 1490/4885MAP3K10 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.